CN109464403A - 茶黄素双没食子酸酯(tfdg)单体冻干粉针剂及其制备方法 - Google Patents

茶黄素双没食子酸酯(tfdg)单体冻干粉针剂及其制备方法 Download PDF

Info

Publication number
CN109464403A
CN109464403A CN201811500379.7A CN201811500379A CN109464403A CN 109464403 A CN109464403 A CN 109464403A CN 201811500379 A CN201811500379 A CN 201811500379A CN 109464403 A CN109464403 A CN 109464403A
Authority
CN
China
Prior art keywords
tfdg
freeze drying
hours
powder injection
drying powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201811500379.7A
Other languages
English (en)
Inventor
蔡昌华
王雷
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Jin Hui Biotechnology Co Ltd
Original Assignee
Jiangsu Jin Hui Biotechnology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Jin Hui Biotechnology Co Ltd filed Critical Jiangsu Jin Hui Biotechnology Co Ltd
Priority to CN201811500379.7A priority Critical patent/CN109464403A/zh
Publication of CN109464403A publication Critical patent/CN109464403A/zh
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/06Free radical scavengers or antioxidants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明公开了茶黄素双没食子酸酯(TFDG)单体冻干粉针剂及其制备方法,处方主要重量份组成为:甘露醇8份;注射用水150份;茶黄素双没食子酸酯(TFDG)2份;柠檬酸‑柠檬酸钠缓冲液适量。本发明冻干粉针剂通过冷冻干燥法制得的,能够保持注射液澄清、透明,同时也进一步增加TFDG的稳定性,避免了高温灭菌对TFDG的破坏,制备出水溶性好、稳定性好、方便于临床应用、疗效好的TFDG注射制剂,可使用药学上可接受的稀释剂进行溶解,溶解后仍然能保持良好的稳定性,可供临床静脉注射使用,扩大了茶黄素的应用范围,为茶黄素今后的药理、毒理学研究以及进一步工业化放大试验提供扎实的基础。

Description

茶黄素双没食子酸酯(TFDG)单体冻干粉针剂及其制备方法
技术领域
本发明属于医药技术领域,具体地说,涉及茶黄素双没食子酸酯(TFDG)单体冻干粉针剂及其制备方法。
背景技术
茶黄素类是茶多酚氧化的产物,化学性质比茶多酚稳定,具有较强的抗氧化特性,其活性不亚于茶多酚,具有多种生理活性和医疗保健作用,是一种极具开发潜力的天然产物。茶黄素具有多种药理功能,如抗肿瘤、抗氧化、抗病毒、抗菌,预防心血管疾病等作用。TFDG在茶黄素众多单体中,抗氧化活性最强,相对于其他单体易于分离纯化,最具开发价值。
有鉴于此特提出本发明。
发明内容
本发明要解决的技术问题在于克服现有技术的不足,提供茶黄素双没食子酸酯(TFDG)单体冻干粉针剂及其制备方法,为解决上述技术问题,本发明采用技术方案的基本构思是:
茶黄素双没食子酸酯(TFDG)单体冻干粉针剂,处方主要重量份组成为:
甘露醇8份;
注射用水150份;
茶黄素双没食子酸酯(TFDG)2份;
柠檬酸-柠檬酸钠缓冲液适量。
茶黄素双没食子酸酯(TFDG)单体冻干粉针剂的制备方法,包括以下步骤:
步骤1,在无菌的操作室内,秤取甘露醇8克,加入150ml溶解,搅拌均匀,精密秤取TFDG原料2克,加入柠檬酸-柠檬酸钠缓冲液调至pH5.0-5.5,加入0.01%的767型针用活性炭,搅拌20分钟,经过0.45μm微孔滤膜过滤,滤液检查澄明度、PH值合格后,再经过0.22μm微孔膜过滤后分装于7ml西林瓶中,每瓶3ml;
步骤2,将西林瓶放入冷冻干燥机中,冻干工艺如下:
-40℃~-30℃预冻4小时,
升温至-30℃~-20℃,7小时,
再升温至-20℃,5小时,
升温至-20℃~-10℃,5小时,
再干燥升温至-10℃,3小时,
继续升温至-10℃~25℃,7小时,
最后25℃,2小时.
步骤3,取出西林瓶,压盖,包装,即得茶黄素双没食子酸酯(TFDG)单体冻干粉针剂。
采用上述技术方案后,本发明与现有技术相比具有以下有益效果。
本发明冻干粉针剂通过冷冻干燥法制得的,能够保持注射液澄清、透明,同时也进一步增加TFDG的稳定性,避免了高温灭菌对TFDG的破坏,制备出水溶性好、稳定性好、方便于临床应用、疗效好的TFDG注射制剂,可使用药学上可接受的稀释剂进行溶解,溶解后仍然能保持良好的稳定性,可供临床静脉注射使用,扩大了茶黄素的应用范围,为茶黄素今后的药理、毒理学研究以及进一步工业化放大试验提供扎实的基础。
具体实施方式
为使本发明实施例的目的、技术方案和优点更加清楚,下面对实施例中的技术方案进行清楚、完整地描述,以下实施例用于说明本发明,但不用来限制本发明的范围。若非特指,所有的份、百分比均为重量单位。
实施例1
茶黄素双没食子酸酯(TFDG)单体冻干粉针剂的制备方法,包括以下步骤:
(1)在无菌的操作室内,秤取甘露醇8克,加入150ml溶解,搅拌均匀,精密秤取TFDG原料2克,加入柠檬酸-柠檬酸钠缓冲液调至pH5.0-5.5,加入0.01%的767型针用活性炭,搅拌20分钟,经过0.45μm微孔滤膜过滤,滤液检查澄明度、PH值合格后,再经过0.22μm微孔膜过滤后分装于7ml西林瓶中,每瓶3ml;
(2)将西林瓶放入冷冻干燥机中,冻干工艺如下:
-40℃~-30℃预冻4小时,
升温至-30℃~-20℃,7小时,
再升温至-20℃,5小时,
升温至-20℃~-10℃,5小时,
再干燥升温至-10℃,3小时,
继续升温至-10℃~25℃,7小时,
最后25℃,2小时.
(3)取出西林瓶,压盖,包装,即得茶黄素双没食子酸酯(TFDG)单体冻干粉针剂。
本发明冻干粉针剂通过冷冻干燥法制得的,能够保持注射液澄清、透明,同时也进一步增加TFDG的稳定性,避免了高温灭菌对TFDG的破坏,制备出水溶性好、稳定性好、方便于临床应用、疗效好的TFDG注射制剂,可使用药学上可接受的稀释剂进行溶解,溶解后仍然能保持良好的稳定性,可供临床静脉注射使用,扩大了茶黄素的应用范围,为茶黄素今后的药理、毒理学研究以及进一步工业化放大试验提供扎实的基础。
以上所述仅是本发明的较佳实施例而已,并非对本发明作任何形式上的限制,虽然本发明已以较佳实施例揭露如上,然而并非用以限定本发明,任何熟悉本专利的技术人员在不脱离本发明技术方案范围内,当可利用上述提示的技术内容作出些许更动或修饰为等同变化的等效实施例,但凡是未脱离本发明技术方案的内容,依据本发明的技术实质对以上实施例所作的任何简单修改、等同变化与修饰,均仍属于本发明方案的范围内。

Claims (4)

1.茶黄素双没食子酸酯(TFDG)单体冻干粉针剂,其特征在于,处方主要重量份组成为:
甘露醇 8份;
注射用水 150份;
茶黄素双没食子酸酯(TFDG) 2份;
柠檬酸-柠檬酸钠缓冲液 适量。
2.如权利要求1所述茶黄素双没食子酸酯(TFDG)单体冻干粉针剂的制备方法,其特征在于,包括以下步骤:
步骤1,在无菌的操作室内,秤处方量取甘露醇,加入注射用水溶解,搅拌均匀,取处方量茶黄素双没食子酸酯(TFDG)原料加入,加入柠檬酸-柠檬酸钠缓冲液调pH;加入针用活性炭,搅拌、过滤,滤液检查澄明度、PH值合格后,再经过微孔膜过滤后,分装于西林瓶中;
步骤2,将西林瓶放入冷冻干燥机中,冷冻干燥后;
步骤3,取出西林瓶,压盖、包装,即得茶黄素双没食子酸酯(TFDG)单体冻干粉针剂。
3.根据权利要求2所述的茶黄素双没食子酸酯(TFDG)单体冻干粉针剂的制备方法,其特征在于,所述步骤1为:在无菌的操作室内,秤取甘露醇8克,加入150ml溶解,搅拌均匀,精密秤取TFDG原料2克,加入柠檬酸-柠檬酸钠缓冲液调至pH5.0-5.5,加入0.01%的767型针用活性炭,搅拌20分钟,经过0.45μm微孔滤膜过滤,滤液检查澄明度、PH值合格后,再经过0.22μm微孔膜过滤后分装于7ml西林瓶中,每瓶3ml。
4.根据权利要求2所述的茶黄素双没食子酸酯(TFDG)单体冻干粉针剂的制备方法,其特征在于,所述步骤2中冷冻干燥工艺包括以下过程:
-40℃~-30℃预冻4小时;
升温至-30℃~-20℃,7小时,
再升温至-20℃,5小时,
升温至-20℃~-10℃,5小时,
再干燥升温至-10℃,3小时,
继续升温至-10℃~25℃,7小时,
最后25℃,2小时。
CN201811500379.7A 2018-12-07 2018-12-07 茶黄素双没食子酸酯(tfdg)单体冻干粉针剂及其制备方法 Pending CN109464403A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201811500379.7A CN109464403A (zh) 2018-12-07 2018-12-07 茶黄素双没食子酸酯(tfdg)单体冻干粉针剂及其制备方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201811500379.7A CN109464403A (zh) 2018-12-07 2018-12-07 茶黄素双没食子酸酯(tfdg)单体冻干粉针剂及其制备方法

Publications (1)

Publication Number Publication Date
CN109464403A true CN109464403A (zh) 2019-03-15

Family

ID=65675969

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201811500379.7A Pending CN109464403A (zh) 2018-12-07 2018-12-07 茶黄素双没食子酸酯(tfdg)单体冻干粉针剂及其制备方法

Country Status (1)

Country Link
CN (1) CN109464403A (zh)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101190909A (zh) * 2006-11-24 2008-06-04 中国农业科学院茶叶研究所 一种制备四种茶黄素单体的方法
CN101744807A (zh) * 2009-12-22 2010-06-23 江苏天晟药业有限公司 表没食子儿茶素没食子酸酯药物组合物及其冻干粉针剂
CN104188922A (zh) * 2014-08-12 2014-12-10 上海东富龙科技股份有限公司 一种羟甲烟胺冻干粉针制剂的制备方法
CN104825402A (zh) * 2015-04-23 2015-08-12 李宝齐 一种含有吉西他滨的注射用药物组合物

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101190909A (zh) * 2006-11-24 2008-06-04 中国农业科学院茶叶研究所 一种制备四种茶黄素单体的方法
CN101744807A (zh) * 2009-12-22 2010-06-23 江苏天晟药业有限公司 表没食子儿茶素没食子酸酯药物组合物及其冻干粉针剂
CN104188922A (zh) * 2014-08-12 2014-12-10 上海东富龙科技股份有限公司 一种羟甲烟胺冻干粉针制剂的制备方法
CN104825402A (zh) * 2015-04-23 2015-08-12 李宝齐 一种含有吉西他滨的注射用药物组合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
YANG, ZIYIN ET AL.: ""Radical-scavenging abilities and antioxidant properties of theaflavins and their gallate esters in H2O2-mediated oxidative damage system in the HPF-1 cells"", 《TOXICOLOGY IN VITRO》 *

Similar Documents

Publication Publication Date Title
CN102670497A (zh) 一种稳定的s-奥拉西坦注射用制剂及其制备方法
KR100897656B1 (ko) 심장-뇌 혈관 질환들 및 안저 질환들 치료용고들빼기로부터 제조된 주사제 및 그것의 제조방법
CN107625967A (zh) 一种特考韦瑞注射用药物组合物及其制备方法
CN102178681B (zh) 一种供注射用的亚叶酸钙组合物及其制备方法
CN102836171A (zh) 一种用于手术及腔镜冲洗的溶液及其制备方法
CN111904936B (zh) 一种法莫替丁冻干粉针剂
CN103446064B (zh) 一种绿原酸粉针剂及其制备方法
CN112618496A (zh) 一种注射用阿奇霉素冻干粉针剂的制备方法
CN109464403A (zh) 茶黄素双没食子酸酯(tfdg)单体冻干粉针剂及其制备方法
CN102614136B (zh) 注射用炎琥宁组合物、冻干粉针剂及其制备方法
CN102068464B (zh) 六神曲抗菌、抗病毒有效部位提取物及其医药用途
CN101019884A (zh) 复方辅酶q10药物制剂及其制备方法和应用
CN110680807B (zh) 一种注射用棓丙酯的制备方法
CN106924195B (zh) 一种注射用紫杉醇脂质体组合物的冻干工艺
CN101376022B (zh) 含聚乙二醇降纤酶的药物组合物
CN1969897A (zh) 治疗心脑血管疾病的药物组合物及其制备方法和质控方法
CN101455646A (zh) 盐酸甲氯芬酯冻干制剂的工艺及其制备方法
CN106176626B (zh) L-丙氨酸-(14-冬凌草甲素)酯胃肠外用药物组合物
CN102836132A (zh) 一种甲磺酸萘莫司他冻干粉针剂
CN109954007A (zh) 一种具有治疗进行性肌营养不良的药物
CN107397722B (zh) 注射用(s)-4-羟基-2-氧代-1-吡咯烷乙酰胺冻干粉及其制备方法
CN1524521A (zh) 注射用曲克芦丁及其制备方法
CN1969916A (zh) 治疗心脑血管疾病的药物组合物及其制备方法和质控方法
CN1969892A (zh) 治疗心脑血管疾病的药物组合物及其制备方法和质控方法
CN1969947A (zh) 治疗心脑血管疾病的药物组合物及其制备方法和质控方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20190315

WD01 Invention patent application deemed withdrawn after publication